Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

New Function of Protein in Cellular Respiration Identified

By Drug Discovery Trends Editor | January 29, 2009

Virginia Commonwealth University researchers have found that the protein Stat3 plays a key role in regulating mitochondria, the energy-producing machines of cells. This discovery could one day lead to the development of new treatments for heart disease to boost energy in failing heart muscle, or to master the abnormal metabolism of cancer.

In the study, researchers reported that Stat3, a protein previously known to control the activity of genes by acting in the cell nucleus, also plays a key role in cellular energy production.

The team examined oxygen consumption in cultured cells and hearts of mice. They discovered that when Stat 3 protein was missing, cells consumed less oxygen and produced less ATP, the key molecular form of cellular energy. The findings revealed that Stat3 is necessary for the function of the mitochondrial electron transport chain that generates ATP. Changes in energy production and expenditure are essential to maintain cellular homeostasis.

‘We found evidence that Stat3 is present in the mitochondria and that it serves to control the production of ATP,’ said principal investigator Andrew C. Larner, M.D., Ph.D., professor of biochemistry and molecular biology in the VCU School of Medicine, and co-leader of the Immune Mechanisms research program at the VCU Massey Cancer Center.

‘We have described a new pathway by which generation of ATP is regulated. This pathway could suggest new ways for Stat3 to be therapeutically manipulated to treat a variety of diseases where there are imbalances between energy generation and energy demands such as occurs in cancer and heart disease,’ he said.

Next, the team will conduct studies to determine the downstream targets of Stat3 in the mitochondria and identify the physiological role of Stat3 that is localized to the mitochondria in heart disease and cancer.

Release Date: January 28, 2009
Source: Virginia Commonwealth University


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

New cell imaging method reveals hidden enzyme activity 
Beyond the silver bullet: Why precision medicine is the next frontier for the $1 trillion obesity market
Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE